Sphera Funds Management LTD. raised its stake in Savara Inc (NASDAQ:SVRA - Free Report) by 115.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,211,533 shares of the company's stock after buying an additional 648,426 shares during the period. Sphera Funds Management LTD. owned about 0.71% of Savara worth $3,719,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Cibc World Markets Corp bought a new position in shares of Savara in the 4th quarter worth $33,000. XTX Topco Ltd bought a new position in shares of Savara in the 4th quarter worth $34,000. Ameriprise Financial Inc. bought a new position in shares of Savara in the 4th quarter worth $37,000. KLP Kapitalforvaltning AS bought a new position in shares of Savara in the 4th quarter worth $41,000. Finally, Hsbc Holdings PLC bought a new position in shares of Savara in the 4th quarter worth $48,000. Institutional investors own 87.93% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.
Check Out Our Latest Report on SVRA
Savara Trading Up 2.0%
Shares of SVRA stock traded up $0.06 on Monday, hitting $3.13. 674,105 shares of the company's stock traded hands, compared to its average volume of 1,302,113. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a one year low of $2.26 and a one year high of $5.11. The company's fifty day simple moving average is $2.94 and its 200 day simple moving average is $3.02. The stock has a market capitalization of $540.98 million, a price-to-earnings ratio of -7.28 and a beta of 0.44.
Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). Equities analysts forecast that Savara Inc will post -0.45 EPS for the current year.
Savara Profile
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Stories
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
